Blood, Lymphatic, Or Bone Marrow Origin Or Derivative Patents (Class 435/372)
  • Patent number: 11891623
    Abstract: Provided herein are isolated neural stem cells and methods of making neural stem cells from human trophoblast stem cells. The isolated neural stem cells can be immune privileged and express one or more protein(s). Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: February 6, 2024
    Assignee: Accelerated BioSciences Corp.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee, Eing-Mei Tsai
  • Patent number: 11873472
    Abstract: The subject invention concerns materials and methods for culture of cell aggregates. The subject invention utilizes three-dimensional (3-D) inserts comprising micro-channels having selected dimensions. The inserts are provided in or on tissue culture plates that can be supported on a programmable rocking platform/station, thereby providing for a hydrodynamic environment that promotes 3-D aggregation of cells cultured on the plates. The supporting rocker is programmed to provide motion that generates hydrodynamic conditions that support 3-D cell aggregation and long-term culture. The subject invention also concerns an apparatus comprising a tissue culture vessel that comprises a 3-D insert of the present invention, and a programmable rocking platform/station that can provide motion to the vessel provided thereon, thereby generating hydrodynamic conditions and wave motion that support 3-D cell aggregation and cell culture. The subject invention also concerns methods for growing 3-D aggregates of cells.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: January 16, 2024
    Inventors: Teng Ma, Ang-Chen Tsai, Xuegang Yuan
  • Patent number: 11845956
    Abstract: Certain populations of small cells present in adult human tissue can undergo activation/development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation/development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 19, 2023
    Assignee: APstem Therapeutics, Inc.
    Inventors: Shaowei Li, Min Hu, Bowen Liu
  • Patent number: 11806368
    Abstract: A method for providing a sub-population of stem cell or plurality of stem cells by determining or modulating GSTT1 expression level or genotype is disclosed together with uses of the stem cells.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 7, 2023
    Assignee: Agency for Science, Technology and Research
    Inventors: Lawrence Stanton, Padmapriya Sathiyanathan, Simon Cool, Victor Nurcombe, Rebekah M. Samsonraj
  • Patent number: 11795433
    Abstract: Disclosed are means, methods, and compositions of matter useful for treatment of neuroinflammation, autoimmunity, transplant rejection, or graft versus host disease (GVHD) comprising exposing autologous immune cells to allogeneic amniotic fluid derived stem cells. In one embodiment peripheral blood mononuclear cells are cultured in the presence of amniotic fluid stem cells in the presence of interleukin-2 for a period of time sufficient to endow tolerogenic properties. Said tolerogenic properties include ability to suppress adaptive or innate immune responses. In another embodiment the invention provides methods of generating antigen specific immune regulatory cells by culture of lymphocytes together with amniotic fluid stem cells in the presence of antigen to which specific immune regulation is desired.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 24, 2023
    Assignee: Creative Medical Technologies, Inc
    Inventors: Thomas Ichim, Amit Patel
  • Patent number: 11771081
    Abstract: A repaired ex vivo organ suitable for transplantation in a human, said repaired ex vivo organ having undergone ex vivo organ perfusion for a maintenance period, wherein said organ had been assessed as being unsuitable for transplantation into a human before the maintenance period and was determined to be suitable for transplantation after the maintenance period.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: October 3, 2023
    Inventors: Shaf Keshavjee, Marcelo Cypel
  • Patent number: 11767500
    Abstract: Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: September 26, 2023
    Assignee: Northeastern University
    Inventor: Shashi K. Murthy
  • Patent number: 11739217
    Abstract: Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.
    Type: Grant
    Filed: January 3, 2023
    Date of Patent: August 29, 2023
    Assignees: VitroLabs Inc, King's College London
    Inventors: Ingvar Helgason, Dusko Ilic
  • Patent number: 11732262
    Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 22, 2023
    Inventors: Souphalone Luangsay, Barbara Testoni, Fabien Zoulim, Soren Ottosen, Lykke Pedersen
  • Patent number: 11723930
    Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 15, 2023
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
  • Patent number: 11725031
    Abstract: Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: August 15, 2023
    Assignee: Biomet Manufacturing, LLC
    Inventors: Joel C. Higgins, Jennifer E. Woodell-May, Jacy C. Hoeppner
  • Patent number: 11725171
    Abstract: A fluid mixing system includes a support housing having an interior surface bounding a chamber. A flexible bag is disposed within the chamber of the support housing, the flexible bag having an interior surface bounding a compartment. An impeller is disposed within the chamber of the flexible bag. A drive shaft is coupled with the impeller such that rotation of the drive shaft facilitates rotation of the impeller. A drive motor assembly is coupled with the draft shaft and is adapted to rotate the drive shaft. An adjustable arm assembly is coupled with the drive motor assembly and is adapted to move the drive motor assembly which in turn moves the position of the drive shaft and impeller. An electrical controller can control movement of the adjustable arm.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 15, 2023
    Inventors: Michael E. Goodwin, Nephi D. Jones
  • Patent number: 11708559
    Abstract: Provided herein are engineered red blood cells expressing rare blood antigen group profiles, and methods of making use the same, are described. Also provided are recombinant reagent red blood cells that express or lack the expression of at least one protein (e.g., a blood group antigen) on its surface and uses thereof.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 25, 2023
    Assignees: The Children's Hospital of Philadelphia, New York Blood Center, Inc.
    Inventors: Stella Chou, Connie Westhoff
  • Patent number: 11655273
    Abstract: Provided are a ligand-bearing substrate which has a surface at least partially coated with a polymer (P3) containing structural units represented by the formulae (1a) and (1b) (in the formulae, R1, R2, X, Y, L, Q1, Q2, Q3, m1, m2 and n are as described in the claims and description); a raw material for such a substrate; and a method for producing such substrates.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 23, 2023
    Inventors: Hiromi Kitano, Tadashi Nakaji, Yuki Usui, Taito Nishino, Takahiro Kishioka
  • Patent number: 11648273
    Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutritive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: May 16, 2023
    Inventor: Michael Har-Noy
  • Patent number: 11638725
    Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: May 2, 2023
    Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
  • Patent number: 11631483
    Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: April 18, 2023
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Anne Brooks, Steve Macrides, Kristin Lanzi
  • Patent number: 11591471
    Abstract: Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: February 28, 2023
    Assignees: VitroLabs Inc, King's College London
    Inventors: Ingvar Helgason, Dusko Ilic
  • Patent number: 11584917
    Abstract: The present invention relates to a chemically defined medium for eukaryotic cell culture, comprising water, at least one carbon source, one or more vitamins, one or more salts, one or more growth factors, one or more fatty acids, one or more buffer components, selenium and one or more further trace elements and its use in the culture of cancer stem cells, in particular tumorsphere culture of cancer stem cells.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 21, 2023
    Assignee: PROMOCELL GMBH
    Inventor: Hagen Wieland
  • Patent number: 11566226
    Abstract: This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: January 31, 2023
    Inventors: Hugh J. M. Brady, Matthew Fuchter, Tomasz Kostrzewski
  • Patent number: 11547727
    Abstract: Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of Fc?RI?. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 10, 2023
    Assignee: ImmunityBio, Inc.
    Inventors: Laurent H. Boissel, Hans G. Klingemann
  • Patent number: 11541078
    Abstract: Described herein are compositions and methods related to use of cardiosphere-derived cells and their extracellular vesicles, such as exosomes and microvesicles, for achieving anti-aging and rejuvenation. This includes discoveries for effects on heart structure, function, gene expression, and systemic parameters. For animal studies, intra-cardiac injections of neonatal rat CDCs was compared to in old and young rats including evaluation of blood, echocardiographic, haemodynamic and treadmill stress tests. For in vitro studies, human heart progenitors from older donors, or cardiomyocytes from aged rats were exposed to human CDCs or cardiosphere derived cell (CDC) derived exosomes (CDC-XO) from pediatric donors. CDCs and CDC-XOs were capable of effectuating youthful patterns of gene expression in the hearts of old, along with a variant of physiological and function benefits, including elongation of telomere length.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: January 3, 2023
    Inventors: Eduardo Marban, Lilian Grigorian
  • Patent number: 11538150
    Abstract: The invention relates to a method of detecting symptoms of peritonitis, wherein the method comprises the following steps: taking a photo of a drainage solution and/or of a catheter exit site using a smartphone and/or inputting at least one query parameter which is input by a patient through the input zone of a smartphone; and, evaluating the photo and/or the query parameter.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: December 27, 2022
    Inventors: Andreas Wuepper, Ulrich Moissl
  • Patent number: 11525135
    Abstract: The invention relates to a composition comprising a double-stranded RNA (dsRNA) having two complementary strands, comprising at least one block of poly A and the complementary block of poly U, each strand having a length of between 50 and 200 bases, preferably between 55 and 200 bases, and a pharmaceutically acceptable vehicle, carrier or excipient, for use in a method of treating a cancer expressing a TLR3 receptor.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: December 13, 2022
    Assignee: TOLLYS
    Inventors: Marc Bonnin, Sylvain Thierry
  • Patent number: 11521168
    Abstract: A first terminal determines a collection date of a somatic cell based on a desired collection date and a collectable date transmitted by a second medium; and outputs the collection date to a first medium. A second terminal outputs the collectable date to the second medium; and determines an acceptance date based on the collection date transmitted by the first medium and a production period of an iPS cell transmitted by a third medium. A third terminal determines the production period based on the collection date and a producible period, and determines a shipment date based on the production period and stockable location and period transmitted by a fourth medium; and outputs the production period to the third medium. A fourth terminal outputs the stockable location and period to the fourth medium; and determines stock location and period based on the production period and the stockable location and period.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: December 6, 2022
    Inventors: Koji Tanabe, Kiyonori Inaba, Masaru Oda
  • Patent number: 11514389
    Abstract: A system for an iPS cell bank includes a terminal and a server. The terminal receives and sends a production request including a desired collection date of a somatic cell and a customer ID to the server. The server stores a collectable date for collecting the somatic cell, a producible period for producing an iPS cell, and a location and a stockable period for stocking the iPS cell; and determines: a collection date based on the desired collection date and the collectable date; a production period based on the collection date and the producible period; an acceptance date of the somatic cell based on the collection date and the production period; a stock location and a stock period based on the production period, the stockable location, and the stockable period; and a shipment date of the iPS cell based on the production period, the stockable location, and the stockable period.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 29, 2022
    Inventors: Koji Tanabe, Kiyonori Inaba, Masaru Oda
  • Patent number: 11464804
    Abstract: A method of treating spinal cord injuries in a patient using sagittal MR images of the spinal cord injury to guide the extent of exposure of the neuro/orthopedic surgeon during a posterior spinal fusion for the purpose of autologous stem cell therapy in the setting of spinal injury; the method using large volumes of the patient's bone marrow aspirated to yield a large quantity of heterogeneous autologous stem cell concentrate containing cellular and subcellular fractions, in addition to soluble protein factors (defined as heterogeneous concentrate) exhibiting regenerative potential which is then applied directly over the spinal cord (under the dura/arachnoid) in the areas affected.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: October 11, 2022
    Inventors: Enrico Stazzone, Madelyn Stazzone
  • Patent number: 11447746
    Abstract: The present invention relates to a method for inducing amplification of human type I NKT cells in vitro using a “specific stimulant+staged cytokine” mode, which consists of two culture stages, wherein the first culture stage focuses on specific amplification of the number of the type I NKT cells, in which a specific stimulant ?-GalCer is used to advantageously amplify the type I NKT cells and ?-GalCer-loaded CD1d-expressing cells are used to stimulate continuous proliferation of the type I NKT cells while adding cytokines IL-2 and IL-7 to assist growth of the type I NKT cells; and the second culture stage is to synchronously perform amplification of the number of the type I NKT cells and guide directed function differentiation, in which CD1d-expressing cells incubated with ?-GalCer continue to stimulate proliferation of the type I NKT cells while adding IL-2, IL-7 and IL-15 to assist amplification of the type I NKT cells and guide differentiation, and IL-12 is added to the culture system 1-2 days before the e
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 20, 2022
    Assignee: Shanghai Innovative Chang'An Biological Technology Co., Ltd.
    Inventors: Jianqing Xu, Xiaoyan Zhang, Jing Wang, Lingyan Zhu
  • Patent number: 11389484
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 19, 2022
    Assignee: Mesoblast International Sárl
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 11319528
    Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: May 3, 2022
    Inventor: Tara L. Deans
  • Patent number: 11248209
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: February 15, 2022
    Assignee: CoImmune, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
  • Patent number: 11219645
    Abstract: Tumor infiltrating lymphocytes (TILs) are white blood cells that are actively recruited to the tumor site to mount an immune response against tumor growth and metastasis. The disclosure provides methods for treating cancer that comprise steps of isolating CD8+ T cells from a sample derived from a subject, expanding the CD8+ T cells in the presence of interleukin-10, and ad ministering the expanded CD8+ T cells to the subject. Methods of treating cancer may be used in combination with inhibitors of the complement signaling pathway.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 11, 2022
    Assignee: Duke University
    Inventors: You-Wen He, Yu Wang
  • Patent number: 11213576
    Abstract: The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 4, 2022
    Inventor: Michael Har-Noy
  • Patent number: 11185348
    Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: November 30, 2021
    Assignee: PROGENA INC.
    Inventors: Alexander Feskov, Irina Feskova, Ievgeniia Zhylkova, Stanislav Zhilkov
  • Patent number: 11174461
    Abstract: The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 16, 2021
    Assignee: Cynata Therapeutics Limited
    Inventors: Igor Slukvin, Gene Uenishi, Derek Hei, Diana Drier
  • Patent number: 11162073
    Abstract: Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonisists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 2, 2021
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
    Inventors: Dhvanit I. Shah, George Q. Daley
  • Patent number: 11154573
    Abstract: Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 26, 2021
    Assignee: The Regents of the University of California
    Inventors: Gay M. Crooks, Amélie Montel-Hagen, Christopher Seet
  • Patent number: 11096997
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: August 24, 2021
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 11028180
    Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 8, 2021
    Assignee: AMGEN INC.
    Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
  • Patent number: 10967054
    Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 6, 2021
    Assignee: SYZ CELL THERAPY CO.
    Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Longqing Tang
  • Patent number: 10889809
    Abstract: The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: January 12, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Thomas Greiner-Stoeffele, Stefan Schoenert
  • Patent number: 10864259
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 15, 2020
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Patent number: 10792309
    Abstract: The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 6, 2020
    Inventors: Mi La Cho, Seok-Goo Cho, Jung-Yeon Lim, Hyun-Sil Park, Min-Jung Park
  • Patent number: 10780096
    Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 22, 2020
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
  • Patent number: 10731130
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14 and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 4, 2020
    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Patent number: 10731129
    Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 4, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Guzman Sanchez-Schmitz, Ofer Levy, Chad Stevens
  • Patent number: 10709762
    Abstract: The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation).
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: July 14, 2020
    Inventor: Michael Sieweke
  • Patent number: 10683482
    Abstract: Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: June 16, 2020
    Assignee: NeuroFx, Inc.
    Inventors: Keith Leonard March, Brian H. Johnstone, Yansheng Du
  • Patent number: 10626372
    Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: April 21, 2020
    Inventors: Bahram Valamehr, Raedun Clarke
  • Patent number: 10584312
    Abstract: The present invention relates to a method for isolating pluripotent/multipotent stem cells derived from umbilical cord blood, characterized by culturing mononuclear cells isolated from umbilical cord blood in a culture vessel containing fibronectin and then harvesting stem cells from the culture, the umbilical cord blood-derived pluripotent/multipotent stem cells isolated thereby; and a cell therapeutic agent containing the pluripotent/multipotent stem cells derived from umbilical cord blood or cells differentiated therefrom. The present invention also relates to a novel culture media for stem cells, a culture method for stem cells which is characterized by culturing and proliferating stem cells in the culture media, and a method for increasing sternness of stem cells which is characterized by a sphere culture or a three-dimensional culture of stem cells.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: March 10, 2020
    Inventors: Kyung Sun Kang, Kyoung Hwan Roh